Cargando…
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias
Levodopa (L-DOPA)-induced dyskinesias (LIDs) represent the major side effect in Parkinson’s disease (PD) therapy. Leucine-rich repeat kinase 2 (LRRK2) mutations account for up to 13 % of familial cases of PD. LRRK2 N-terminal domain encompasses several serine residues that undergo phosphorylation in...
Autores principales: | Stanic, Jennifer, Mellone, Manuela, Cirnaru, Maria Daniela, Perez-Carrion, Maria, Zianni, Elisa, Di Luca, Monica, Gardoni, Fabrizio, Piccoli, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866295/ https://www.ncbi.nlm.nih.gov/pubmed/27169991 http://dx.doi.org/10.1186/s13041-016-0234-2 |
Ejemplares similares
-
NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
por: Mellone, Manuela, et al.
Publicado: (2015) -
LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate
por: Belluzzi, Elisa, et al.
Publicado: (2016) -
Cerebellum in Levodopa-Induced Dyskinesias: The Unusual Suspect in the Motor Network
por: Kishore, Asha, et al.
Publicado: (2014) -
Rabphilin-3A Drives Structural Modifications of Dendritic Spines Induced by Long-Term Potentiation
por: Franchini, Luca, et al.
Publicado: (2022) -
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)